Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes

Experimental Hematology

Volumn 35, Issue 5, 2007, Pages 842-853

  Kornblau, Steven M ^a   Aycox, Preston G ^a   Stephens, L Clifton ^a   McCue, David ^a   Champlin, Richard E ^a   Marini III, Frank C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL TRANSPLANTATION; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LETHAL DOSE; LEUKEMIA; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BONE MARROW TRANSPLANTATION; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GANCICLOVIR; GRAFT VS HOST DISEASE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; LEUKEMIA; MALE; MICE; MICE, INBRED AKR; PHENOTYPE; RETROVIRIDAE; SURVIVAL RATE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS;

MURINAE; MUS; SIMPLEXVIRUS;

EID: 34247156650     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.02.008     Document Type: Article

References (42)

1. Biggs J.C., Horowitz M.M., Gale R.P., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80 (1992) 1090-1093
2. Sullivan K.M. Graft-versus-host-disease. In: Thomas E.D., Blume K.G., and Forman S.J. (Eds). Hematopoietic Cell Transplantation. 2nd ed. (1999), Blackwell Science, Oxford 515-536
3. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 91 (1998) 1083-1090
4. Sadelain M., and Riviere I. Sturm und drang over suicidal lymphocytes. Mol Ther 5 (2002) 655-657
5. Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997) 1719-1724
6. Bonini C., Verzeletti S., Servida P., et al. Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after allo-BMT. Blood 84 Suppl 1a (1994) 110a (Abstract)
7. Burger S.R., Kadidlo D.M., Basso L., Bostrom N., and Orchard P.J. Cellular engineering of HSV-tk transduced expanded T lymphocytes for graft-versus-host-disease management. Acta Haematol 110 (2003) 121-131
8. Tiberghien P., Reynolds C.W., Keller J., et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?. Blood 84 (1994) 1333-1341
9. Munshi N.C., Govindarajan R., Drake R., et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 89 (1997) 1334-1340
10. Marini F.C., and Kornblau S.M. Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition. Bone Marrow Transplant 23 (1999) 907-915
11. Smith K., Galloway K., Kennell W.L., Ogilvie K.K., and Radatus B.K. A new nucleoside analog, 9-{[2-hydroxy-1-(hydroxymethy)ethoxyl] methyl guanine}, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 22 (1982) 55-61
12. Faulds D., and Heel R.C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 39 (1990) 597-638
13. Tiberghien P., Cahn J.Y., Lioure B., et al. Herpes-simplex thymidine-kinase-expressing donor T cells administered with a T-cell-depleted marrow graft: In vivo depletion of gene-modified donor T cells. Blood 92 (1998) 691a (Abstract)
14. Ciceri F., Bonini C., Marktel S., et al. Long term follow-up in 30 patients receiving HSV-TK transduced donor lymphocytes after allo-BMT. Blood 94 Suppl 1 (1999) 668a (Abstract)
15. Champlin R., Bensinger W., Henslee-Downey P.J., et al. Phase I/II study of thymidine kinase (TK)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies. Blood 94 Suppl 1 (1999) 324a (Abstract)
16. Munshi N., Tricot G., Jagannath S., et al. Clinical results of thymidine kinase (TK) gene transduced donor lymphocyte infusion following allogeneic transplantation in myeloma. Blood 90 (1997) 111a (Abstract)
17. Burt R.K., Drobyski W.R., Seregina T., et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 31 (2003) 903-910
18. Di Ianni M., Di Florio S., Venditti G., et al. T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection. Cancer Gene Ther 7 (2000) 920-926
19. Robinet R., Fehse B., Ebeling S., Sauce D., Ferrand D., and Tiberghien P. Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function. Cytotherapy 7 (2005) 150-157
20. Coito S., Sauce D., Duperrier A., et al. Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation- and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells. Stem Cells Dev 13 (2004) 71-81
21. Duarte R.F., Chen F.E., Lowdell M.W., Potter M.N., Lamana M.L., and Prentice H.G. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy. Gene Ther 9 (2002) 1359-1368
22. Contassot E., Angonin R., Pavy J., et al. In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. Transplantation 65 (1998) 1365-1370
23. Ciceri F., Bonini C., Gallo-Stampino C., and Bordignon C. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy 7 (2005) 144-149
24. Contassot E., Ferrand C., Angonin R., et al. Ganciclovir-sensitive acute graft-versus-host disease in mice receiving herpes simplex virus-thymidine kinase-expressing donor T cells in a bone marrow transplantation setting. Transplantation 69 (2000) 503-508
25. Helene M., Lake-Bullock V., Bryson J.S., Jennings C.D., and Kaplan A.M. Inhibition of graft-versus-host disease use of a t cell-controlled suicide gene. J Immunol 158 (1997) 5079-5082
26. Litvinova E., Maury S., Boyer O., et al. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood 100 (2002) 2020-2025
27. Drobyski W.R., Gendelman M., Vodanovic-Jankovic S., and Gorski J. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. J Immunol 170 (2003) 3046-3053
28. Rettig M.P., Ritchey J.K., Prior J.L., Haug J.S., Piwnica-Worms D., and DiPersio J.F. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J Immunol 173 (2004) 3620-3630
29. Kornblau S.M., Stiouf I., Snell V., et al. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Res 61 (2001) 3355-3360
30. Truitt R.L., and Atasoylu A.A. Contribution of CD4+ and CD8+ T-cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8 (1991) 51-58
31. Truitt R.L., and Atasoylu A.A. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 77 (1991) 2515-2523
32. Johnson B.D., and Truitt R.L. A decrease in graft-vs-host disease without loss of graft-vs. leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation 54 (1992) 104-112
33. Johnson B.D., and Truitt R.L. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85 (1995) 3302-3312
34. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 (2002) 575-581
35. Li Z., Dullmann J., Schiedlmeier B., et al. Murine leukemia induced by retroviral gene marking. Science 296 (2002) 497
36. Yotnda P., Zompetta C., Andreeff M., Brenner M.K., and Marini F.C. Comparison of the transduction efficiency of leukemic cells with different fiber-modified adenoviruses. Hum Gene Ther 15 (2004) 1229-1242
37. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
38. + T cells do not induce graft-versus-host-disease. J Clin Invest 112 (2003) 101-108
39. Uharek L., and Mueller-Ruchholtz W. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease. Ann Hematol 64 (1992) 225-259
40. Bachar-Lustig E., Rachamim N., Li H.W., Lan F., and Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1 (1995) 1268-1273
41. Matte C.C., Cormier J., Anderson B.E., et al. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood 103 (2004) 4353-4361
42. Marktel S., Magnani Z., Ciceri F., et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101 (2003) 1290-1298